Transplantation of multi-potent mesenchymal stromal cells for the treatment of graft-versus-host reaction
- Authors: Grigoryan A.S.
- Issue: Vol 1, No 3 (2006)
- Pages: 31-32
- Section: Cell technology
- Submitted: 21.02.2023
- Accepted: 21.02.2023
- Published: 15.03.2006
- URL: https://genescells.ru/2313-1829/article/view/261334
- DOI: https://doi.org/10.23868/gc261334
- ID: 261334
Cite item
Full Text
About the authors
A. S. Grigoryan
Author for correspondence.
Email: redaktor@celltranspl.ru
Russian Federation
References
- Thomas E.D., Buckner C.D., Banaji M. et al. One hundred patients with acute leukaemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511 -33.
- Appelbaum F. The current status of hematopoietic cell transplantation. Annu. Rev. Med. 2003; 54: 491-512.
- Aschan J. Treatment of moderate to severe acute graft-versus-host disease: a retrospective analysis. Bone Marrow Transplant. 1994; 14: 601 -7.
- Angeloupoulou M., Novelli E., Grove J.E. et al. Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Exp. Hematol. 2003; 31: 413-20.
- Maitra B., Szekely E., Gjini K. et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 2004; 33: 597-604.
- Tse W.T., Pendleton J.D., Beyer W.M. et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75: 389-97.
- Klyushnenkova E., Mosca J.D., Zernetkina V. et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance and suppression. Biomed. Science 2005; 12: 47-57.
- Rasmusson I., Ringde' n O., Sundberg B. et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76: 1208.
- Le Blanc K., Rasmusson I., Sundberg B. et al. Treatment of severe acute graft-versus-host disease with third party haplo-identical mesenchymal stem cells. Lancet 2004; 363: 1439-41.